What does CUSIP 45845PAB4 represent in this 13F holders report?

CUSIP 45845PAB4 is the security identifier for 45845PAB4 - INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 used to aggregate holder disclosures.

How many institutions held 45845PAB4 - INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 in Q1 2024?

No institutional holders were reported for 45845PAB4 - INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 in Q1 2024; review adjacent reporting periods for trend context.

INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1

CUSIP: 45845PAB4

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class: Debt / NOTE 2.000% 5/1
Total 13F principal: $0
Principal change: -$3,000,000
Total reported market value: $0
Number of holders: 0
Value change: -$2,973,750
Number of sells: 1

Quarterly Holders Quick Answers

What is CUSIP 45845PAB4?
CUSIP 45845PAB4 identifies 45845PAB4 - INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2023

Recent filing periods for CUSIP 45845PAB4:

Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022

INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1

Q1 2024 13F Holders as of 31 Mar 2024

Quarterly Holders Quick Answers

Related Filing Research

Explore More Reporting Periods

There are no holders of INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 as of Q1 2024.